[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344573-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-344573-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","the-vascular-densityangiogenesis-marker-cd31pecam1-does-not-correlate-with-overall-survival-in-neuroendocrine-tumors","The Vascular Density/Angiogenesis Marker CD31/PECAM1 does not Correlate with Overall Survival in Neuroendocrine Tumors","","Neuroendocrine neoplasms (NENs) are rare cancers. CD31/PECAM1 is an adhesion molecule linked to endothelial cell-to-cell contact, and increased CD31 expression is often treated as a marker of tumor growth and aggressiveness. This study evaluates whether CD31 expression in primary and metastatic NEN tumors correlates with overall survival and pathological metrics, tumor grade, and anatomic location. CD31 staining was quantified and cross-referenced with survival outcomes for 2004–2024 surgical cases.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-vascular-densityangiogenesis-marker-cd31pecam1-does-not-correlate-with-overall-survival-in-neuroendocrine-tumors/344573/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-vascular-densityangiogenesis-marker-cd31pecam1-does-not-correlate-with-overall-survival-in-neuroendocrine-tumors/344573.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of this study on CD31/PECAM1 in neuroendocrine tumors?","Question",{"text":63,"@type":64},"The study aims to determine the prognostic value of CD31 expression in primary and metastatic NEN tumors and test correlations with overall survival and pathological metrics, including tumor grade and location.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were CD31 levels measured and what data source was used?",{"text":68,"@type":64},"NEN tumors were routinely stained for CD31, and quantification was performed by staff pathologists with results documented in pathology reports and stored in the rare cancer program RedCap database covering surgical activity from 2004 to 2024.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings regarding CD31 staining and overall survival?",{"text":72,"@type":64},"Across 913 NET patients, CD31 staining levels did not differ significantly by primary site, tumor grade, or between matched primary and metastatic tumors, and there was no correlation between CD31 staining and overall survival (r = 0.01).",{"name":74,"@type":61,"acceptedAnswer":75},"What conclusion does the study draw about using CD31 as a prognostic biomarker in NEN?",{"text":76,"@type":64},"Despite CD31’s role in angiogenesis and tumor phenotype, the study found no identifiable measurable or prognostic clinical value from high CD31 levels for NEN outcomes.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},344573,1790179557,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":119,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Journal of Gastrointestinal Cancer (2026) 57:4 [https://doi.org/10.1007/s12029-025-01381-y](https://doi.org/10.1007/s12029-025-01381-y)  \nRESEARCH  \nThe Vascular Density/Angiogenesis Marker CD31/PECAM1 does not Correlate with Overall Survival in Neuroendocrine Tumors  \nNicholas J. Skill1,2 · Kenneth Avanzino2 · Yvette Bren-Mattison2 · J. Philip Boudreaux2 · RamcharanThiagarajan2 · Mary Maluccio2  \nAccepted: 20 December 2025 © The Author(s) 2026  \nAbstract Neuroendocrine neoplasms (NENs) are rare cancers. CD31/PECAM1 is an adhesion molecule that modulatesendothelial cell-to-cell contact. Increased CD31 expression is a marker for tumor growth, and cancer aggressiveness. The purpose of this study was to better understand the prognostic value of CD31 expression in primary and metastatic NEN tumors in terms of correlations with overall survival and pathological metrics, tumor grade, and tumor primary/metastatic location. As NENs are highly vascular tumors, the hypothesis is that CD31 staining is an important prognostic biomarker and target. This is based on prior correlations between CD31 staining and 3-year recurrence-free survival in pancreas NENs. Methods NEN tumors, surgically removed within our dedicated multi state southern regional neuroendocrine program, are routinely stained for CD31 . Quantification of CD31 staining was performed by staff pathologists and documented in the pathology report within the patient medical record and stored in the rare cancer program RedCap database. The database covers surgical activity between 2004 and 2024. The database was queried for NET patients with quantified CD31 levels (number of positive vessels per high power field (HPF)) in primary or metastatic NEN tumors. CD31 levels were cross referenced against demographics, tumor grade, primary and metastatic tumor location, and overall survival.  \nResults Nine hundred and thirteen NET patients were identified. Primary tumor: Small Bowel (74%), Pancreas (15%), Lung (2%), Stomach (5%), & Rectum (4%) . Demographics: Female 59±8.6%, Non-Hispanic 93.4±2%, White/Caucasian 70.4±14 .3%, & Black/African American 21.6±16% . Grade: G1 45±8%, G2 44±3 .6, G3 11±5 . 8% . There were no statistical differences in CD31 staining levels (cells/HPF) between (1) NEN tumors from small bowel (33 ± 17), pancreas (39.7 ±34), lung (44 ± 27), stomach (39 ± 27), and rectum (32 ± 19) (p >0.05),(2) tumor grade (G1. 31 ± 16; G2. 30 ± 16; and G3. 25 ± 12)(p >0.05),(3) between matched primary and metastatic tumors (lymph node metastasis. 29 ± 16 vs. primary tumor 30 ± 14 (p = 0.46); liver metastasis 30 ± 18 vs. primary tumor 32 ± 17 (p = 0.17), & (4) no correlation between CD31 staining and overall survival (r = 0.01) .  \nConclusion NEN tumors are highly vascularized and consistently positive for CD31 . Despite reports that CD31/PACAM1 is important to cell adhesion and tumor phenotype, there was no identifiable measurable impact of high CD31 levels on NEN. Nor was there a prognostic clinical value for CD31 staining quantification.  \n􀀍 Nicholas J. Skill [nskill@lsuhsc.edu](nskill@lsuhsc.edu)  \n1 Department of Interdisciplinary Oncology, Louisiana State University Health Science Center, New Orleans, LA 70112, USA  \n2 Department of Surgery, Louisiana State University Health Science Center, New Orleans, LA 70112, USA  \nIntroduction  \nVascular density has been defined as the proportion of the total area of tissue occupied by vessels and has been linked to oncological features and therapeutic outcomes associated with cancer [1–4] . Angiogenesis is the process of forming new blood vessels and has been linked to increased vascular density and cancer growth/metastasis [5–8]. Staining for the endothelial cell marker protein CD31 is a well-standardized  \n1 3  \nmethodology to assess angiogenesis and microvascular density [1] . In particular, studies have shown that CD31 contributes to (1) peritoneal metastasis of colorectal cancer by promoting epithelial-mesenchymal transition, and (2) h","cbCaiuis6DgNG8la","https://ap.wps.com/l/cbCaiuis6DgNG8la","pdf",979577,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What is the main objective of this study on CD31/PECAM1 in neuroendocrine tumors?\",\"answer\":\"The study aims to determine the prognostic value of CD31 expression in primary and metastatic NEN tumors and test correlations with overall survival and pathological metrics, including tumor grade and location.\"},{\"question\":\"How were CD31 levels measured and what data source was used?\",\"answer\":\"NEN tumors were routinely stained for CD31, and quantification was performed by staff pathologists with results documented in pathology reports and stored in the rare cancer program RedCap database covering surgical activity from 2004 to 2024.\"},{\"question\":\"What were the key findings regarding CD31 staining and overall survival?\",\"answer\":\"Across 913 NET patients, CD31 staining levels did not differ significantly by primary site, tumor grade, or between matched primary and metastatic tumors, and there was no correlation between CD31 staining and overall survival (r = 0.01).\"},{\"question\":\"What conclusion does the study draw about using CD31 as a prognostic biomarker in NEN?\",\"answer\":\"Despite CD31’s role in angiogenesis and tumor phenotype, the study found no identifiable measurable or prognostic clinical value from high CD31 levels for NEN outcomes.\"}]","The Vascular Density/Angiogenesis Marker CD31/PECAM1 does not Correlate with Overall Survival in Neuroendocrine Tumors | PDF",1790054498,23,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5479983ae2b96c8652ad440d23a727e.webp",983,1305,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c40b105bf6691efa62358d855546f6a6.webp",982,1304,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a8b27d4d78f5465c5b0c39a69adea54.webp",981,1303,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e83829fedae44b3caaf3ff7d81a9a30.webp",980,1301]